FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVA	L
OMB Number:	3235-0287
Estimated average burden	hours
ner resnonse	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Ventech Capital II				•	EYEG]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner			
(Last) (First) (Middle) 47 AVENUE DE L'OPERA			nth/Da	ay/Year)		Officer (give title below) Other	specify below)		
(Street) PARIS CEDEX 07, I0 75002				nth/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
2. Transaction Date (Month/Day/Yea	Execution Date, if any	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	Beneficial
	(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price			Ownership (Instr. 4)
02/19/2015		С		506,563	A	<u>(1)</u>	506,563	D	
02/19/2015		C		142,218	A	<u>(2)</u>	648,781	D	
02/19/2015		C		501,405	A	<u>(3)</u>	1,150,186	D	
02/19/2015		С		241,270	A	\$ 4.2	1,391,456	D	
02/19/2015		P		102,777	A	\$ 6	1,494,233	D	
ass of securities benefici:	ally owned directly or	F	orm a	are not rec	quired to	respo			1474 (9-02)
	(Middle) (Zip) 2. Transaction Date (Month/Day/Yea 02/19/2015 02/19/2015 02/19/2015 02/19/2015 02/19/2015	(Middle) 3. Date of Earliest Tran 02/19/2015 4. If Amendment, Date (Zip) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 02/19/2015 02/19/2015 02/19/2015 02/19/2015 02/19/2015 02/19/2015	EYEGATE PHARMACEUT 3. Date of Earliest Transaction (Mor 02/19/2015 4. If Amendment, Date Original File 1.	EYEGATE PHARMACEUTICA	Cape Cape	EYEGATE PHARMACEUTICALS INC [EYEG]	EYEGATE PHARMACEUTICALS INC [EYEG]	EYEGATE PHARMACEUTICALS INC [EYEG] Officer (give title below) Officer (give title be	EYEGATE PHARMACEUTICALS INC [EYEG] Check all applicable Check all applicable Check Applicable Check Check

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	Derivative Securities Beneficially	Ownership Form of Derivative	Beneficial Ownership
				Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect	(Instr. 4)
Series B Preferred Stock	(1)	02/19/2015		С			11,801	<u>(1)</u>	<u>(1)</u>	Common Stock	11,801	\$ 0	0	D	
Series C Preferred Stock	<u>(2)</u>	02/19/2015		С			17,363	(2)	<u>(2)</u>	Common Stock	17,363	\$ 0	0	D	
Series D Preferred Stock	(3)	02/19/2015		С			140,685	(3)	(3)	Common Stock	140,685	\$ 0	0	D	
Convertible Promissory Note	\$ 4.2	02/19/2015		P		\$ 1,013,334		02/19/2015	06/06/2015	Common Stock	241,270	\$ 1,013,334	\$ 1,013,334	D	
Convertible Promissory Note	\$ 4.2	02/19/2015		C			\$ 1,013,334	02/19/2015	06/06/2015	Common Stock	241,270	\$ 0	0	D	

Reporting Owners

B # 0 Y /	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Ventech Capital II 47 AVENUE DE L'OPERA PARIS CEDEX 07, I0 75002		X						

Signatures

/s/ Alain Caffi, Chairman of Managing Board*	02/23/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 10.94-for-one basis, and had no expiration date.
- (2) Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 9.60-for-one basis, and had no expiration date.
- (3) Upon closing of the Issuer's initial public offering, each share of Series D Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 10.96-for-one basis, and had no expiration date.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.